The cell and gene therapy market is a rapidly growing segment of the biopharmaceutical industry, driven by advances in genetics, biotechnology, and regenerative medicine. These therapies involve the use of living cells or genetic material to treat or cure diseases that were previously untreatable or incurable. The market is expected to experience significant growth over the next few years, with a surge in clinical trials, FDA approvals, and investment in research and development. However, the high cost of these therapies, the need for specialized manufacturing facilities, and the complexity of clinical trials pose challenges to their widespread adoption. As such, ongoing efforts to develop more efficient manufacturing processes and to streamline clinical trial design and implementation are critical to the future success of the cell and gene therapy market.
Global Cell and Gene Therapy Market size was valued at US$ 15,580.3 Million in 2022 and is expected to witness a CAGR of 24.7% over the forecast period (2022 – 2030).
Market Players in the Cell And Gene Therapy Industry:
1. Amgen
Amgen is a biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. It operates in more than 100 countries and provides treatments in areas such as oncology, hematology, and cardiovascular diseases. In June, 2021 Amgen has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc
2. Biogen
Biogen is a biotechnology company founded in 1978 and headquartered in Cambridge, Massachusetts. It operates in more than 40 countries and provides treatments in areas such as neurology, immunology, and rare diseases. Jan. 04, 2023 Biogen Inc. and Alcyone Therapeutics have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRx™ System, an implantable medical device intended for subcutaneous delivery of antisense oligonucleotide (ASO) therapies into the intrathecal space.
3. BioMarin
BioMarin Pharmaceuticals is a biotechnology company founded in 1997 and headquartered in San Rafael, California. It operates in more than 50 countries and provides treatments for rare genetic diseases.
4. Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is a pharmaceutical company founded in 1858 and headquartered in New York City, New York. It operates in more than 70 countries and provides treatments in areas such as oncology, cardiovascular diseases, and immunology. In September, 2022 announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu™ (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
5. GlaxoSmithKline
GlaxoSmithKline is a pharmaceutical company founded in 2000 and headquartered in Brentford, United Kingdom. It operates in more than 100 countries and provides treatments in areas such as respiratory, HIV, and vaccines. In February, 2023 GSK plc reports that the US Food and Drug Administration (FDA) granted full approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a US FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.
6. Novartis
Novartis is a pharmaceutical company founded in 1996 and headquartered in Basel, Switzerland. It operates in more than 140 countries and provides treatments in areas such as oncology, immunology, and ophthalmology. In March, 2023 Sandoz, a global leader in generic and biosimilar medicines, today signed a Memorandum of Understanding (MOU) to build a new biologics production plant in Lendava, Slovenia.
7. Pfizer
Pfizer is a pharmaceutical company founded in 1849 and headquartered in New York City, New York. It operates in more than 125 countries and provides treatments in areas such as oncology, cardiology, and vaccines. In January, 2023 Gero announced that it has entered into a research collaboration with Pfizer to apply Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data.
8. Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc is a biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It operates in more than 30 countries and provides treatments in areas such as ophthalmology, oncology, and immunology. In November, 2022 Regeneron And Cytomx Announce Strategic Research Collaboration In The Field Of Conditional Bispecific Therapeutics For The Treatment Of Cancer.
9. Spark Therapeutics
Spark Therapeutics is a biotechnology company founded in 2013 and headquartered in Philadelphia, Pennsylvania. It operates in several countries and provides gene therapy treatments for inherited retinal diseases, hemophilia, and other genetic diseases.
10. Agilis Biotherapeutics
Agilis Biotherapeutics is a biotechnology company founded in 2013 and headquartered in Cambridge, Massachusetts. It focuses on developing gene therapies for rare genetic diseases.
11. Angionetics
Angionetics is a biotechnology company founded in 2009 and headquartered in New York City, New York. It develops treatments for peripheral artery disease and other vascular disorders.
*Definiton- Cell and gene therapy are innovative medical treatments that use living cells or genetic material to treat or cure diseases. These therapies have the potential to address a wide range of medical conditions, including genetic disorders, cancer, and autoimmune diseases, by repairing or replacing damaged or missing cells or genes.
